Identification of linear human B-cell epitopes of tick-borne encephalitis virus

  • Suvi Kuivanen1Email author,

    Affiliated with

    • Jussi Hepojoki1,

      Affiliated with

      • Sirkka Vene4,

        Affiliated with

        • Antti Vaheri1 and

          Affiliated with

          • Olli Vapalahti1, 2, 3

            Affiliated with

            Virology Journal201411:115

            DOI: 10.1186/1743-422X-11-115

            Received: 28 March 2014

            Accepted: 13 June 2014

            Published: 19 June 2014

            Abstract

            Background

            Tick-borne encephalitis (TBE) is a central nervous system infection transmitted to humans by ticks. The causative agent, tick-borne encephalitis virus (TBEV), belongs to the genus Flavivirus (family Flaviviridae), which includes globally important arthropod-borne viruses, such as dengue, Yellow fever, Japanese encephalitis and West Nile viruses. Flaviviruses are highly cross-reactive in serological tests that are currently based on viral envelope proteins. The envelope (E) protein is the major antigenic determinant and it is known to induce neutralizing antibody responses.

            Methods

            We synthesized the full-length TBEV proteome as overlapping synthetic 18-mer peptides to find dominant linear IgG epitopes. To distinguish natural TBEV infections from responses to TBE immunization or other flavivirus infections, the peptides were probed with sera of patients infected with TBEV, West Nile virus (WNV) or dengue virus (DENV), sera from TBE vaccinees and negative control sera by SPOT array technique.

            Results

            We identified novel linear TBEV IgG epitopes in the E protein and in the nonstructural protein 5 (NS5).

            Conclusions

            In this study, we screened TBEV structural and nonstructural proteins to find linear epitopes specific for TBEV. We found 11 such epitopes and characterized specifically two of them to be potential for differential diagnostics. This is the first report of identifying dominant linear human B-cell epitopes of the whole TBEV genome. The identified peptide epitopes have potential as antigens for diagnosing TBEV and to serologically distinguish flavivirus infections from each other.

            Keywords

            Epitope Flavivirus Tick-borne encephalitis virus

            Introduction

            Tick-borne encephalitis virus (TBEV) is one of the most important neurotropic arthropod-borne pathogens in Europe, causing nearly 3000 hospitalizations annually [1]. TBEV is endemic in many European countries, Russia and China. It is mainly transmitted by Ixodes ticks, but can also be transmitted via consumption of unpasteurized goat milk [2, 3]. There are three subtypes of TBEV circulating in geographically distinct areas; namely European, Siberian, and Far Eastern. The variation at amino acid level is up to 5.6% between subtypes and 2.2% within a subtype [4].

            The flavivirus virion is approximately 50 nm in diameter and displays icosahedral symmetry. The virion consists of three structural proteins (capsid C, prM and envelope E), the RNA genome, and a lipid membrane derived from the host cell. The flavivirus genome is a single-stranded positive-sense RNA (approximately 11 kilobases), which is encapsidated by the C protein. The genome contains a single open reading frame, which encodes a polyprotein that is co- and post-translationally cleaved into ten proteins by viral and host proteases. The envelope protein E is a class II viral fusion protein. It consists of three distinct domains (I, II and III), and forms homodimers in a head to tail manner. In the virion, the homodimers further arrange into trimers parallel to each other. The other envelope protein, prM, is cleaved by furin during viral maturation and the pr moiety is released as a result of conformational changes. The seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) are found in the infected cell. NS1 is the only nonstructural protein that is glycosylated and secreted outside the cell. NS3 and NS2B form the viral serine protease that is required for post-translational modification of the polyprotein [5]. NS5 is a multifunctional protein containing an N-terminal methyl transferase domain and a C-terminal RNA-dependent RNA polymerase domain [6, 7]. The other small nonstructural proteins (NS2A, NS4A and NS4B) are expected to function at least in the genome replication [8].

            To date, the E and NS1 proteins are known to raise protective antibodies in infected humans, monkeys and mice [9]. PrM, does not elicit protective antibodies, but is probably required for the preservation of conformational epitopes of the E protein [10]. Previous studies suggest that infections with dengue (DENV), Japanese encephalitis (JEV) and West Nile (WNV) viruses can be differentiated by the antibody response to the prM protein [10, 11]. For DENV type 1, some of the dominant epitopes in E and NS1 proteins have been identified using protein fragmentation methods [9]. In addition, AnandaRao et al. characterized several immunodominat linear B-cell epitopes in C and NS4A proteins of DENV using multi-pin peptide synthesis strategy [12].

            In the present study, we used a peptide-based approach to identify immunodominat linear B-cell epitopes from the entire TBEV genome, which have not been previously reported. We found TBEV-specific peptides in the E and NS5 proteins. The characterized epitopes showed potential in differentiating between other flavivirus infections, and between natural and vaccine-derived immunity to TBEV.

            Results

            Proteome-wide epitope screening

            A total of 567 overlapping linear 18-mer peptides were initially probed with pools of TBEV-seronegative, acute TBEV-seropositive sera, and a pool of sera from TBEV-immunized individuals. Several epitope regions were identified in both structural and nonstructural parts of the TBEV proteome as highlighted by squares (peptides positive with either TBEV seropositive or TBEV-immunized pool) and circles (peptides positive only by TBEV-immunized pool) in Figure 1A. We used densitometry to quantify the signal intensities of the peptides given by each pool, and plotted the signal intensity on a graph in parallel with Kyte and Doolittle hydrophilicity plots (Figure 1B). This quite expectedly showed that the antigenic regions overlapped with the hydrophilic regions throughout the proteome. To study which of the epitopes are dominant in TBEV-seropositive individuals, we probed the membrane next with individual serum samples of the TBEV seropositive serum pool. Peptides that were positive in at least 4/5 of the acute-phase samples, but remained negative in densitometric quantification with seronegative pool, were selected for further analysis (highlighted by squares in Figure 1A). In total, we identified 11 such IgG epitopes throughout the TBEV proteome (Table 1).
            http://static-content.springer.com/image/art%3A10.1186%2F1743-422X-11-115/MediaObjects/12985_2014_2446_Fig1_HTML.jpg
            Figure 1

            SPOT array of TBEV proteome as overlapping peptides and prediction of antigenic regions. A) SPOT array of TBEV coding region, acute TBEV-seropositive pool spots in rectangle, TBEV-immunized spots in circles, i) acute TBEV-seropositive serum pool, ii) TBEV-seronegative serum pool and iii) TBEV-immunized serum pool. B) Kyte and Doolittle hydrophilicity plot of the TBEV genome corresponds to the signal intensities from the TBEV-seropositive and –negative serum pools. The window in Kyte and Doolittle hydrophilicity plot is 18. Amino acids in X-axis, signal intensities of the SPOT array in Y (TBEV-seropositive in blue, TBEV-seronegative in red), hydrophilicity (above) and hydrophobicity (below) in the upper X-axis.

            Table 1

            Proteome-wide TBEV-specific linear epitope mapping

            Protein

            Index

            Virus

            Peptide sequence

            Sensitivity

            Vaccinated

            E

            56

            TBEV

            E N P A K T R E Y C L H A K L S D T

            4/5

            +

            E

            74

            TBEV

            G R K T A S F T V S S E K T I L T M

            4/5

            -

            E

            85

            TBEV

            L P W K H E G A Q N W N N A E R L V

            5/5

            +

            NS1

            154

            TBEV

            E C P L E R R K T G V F T V A E F G

            4/5

            -

            NS2B

            244

            TBEV

            A G L A A S A I H W S G I L G V M G

            4/5

            +

            NS3

            340

            TBEV

            P W L A W H V A A N V S S V T D R S

            4/5

            -

            NS4B

            382

            TBEV

            S E W T N V D I Q P A R S W G T Y V

            4/5

            -

            NS5

            521

            TBEV

            A L N T L T N I K V Q L I R M M E G

            4/5

            +

            NS5

            531

            TBEV

            P L D D R F G K A L Y F L N D M A K

            4/5

            -

            NS5

            532

            TBEV

            G K A L Y F L N D M A K T R K D I G

            4/5

            -

            NS5

            552

            TBEV

            W S I H A S G A W M T T E D M L D V

            5/5

            -

            Epitope characterization

            To further fine-map the identified eleven peptide epitopes, a new set of overlapping 18-mer peptides with a single amino acid shift were synthesized from a region including six additional amino acids in both N- and C-termini of the parent peptide, resulting in a total of 13 peptides per each originally selected peptide. To evaluate the potential cross-reactivity between flaviviruses, we included the region corresponding to the parent peptide from heterologous flaviviruses (Table 2). The novel array was probed individually with a new panel of paired sera from six TBE-patients and 20 TBEV-seronegative sera (Table 3). With these samples, three of the original 11 peptides remained positive, two in E (E-74/38 and E-85/59) and one in NS5 (NS5-521/198), when using a limit of at least 4/6 TBE-patients positive (in either acute or convalescent sample) and no more than 2/20 of TBEV-seronegative samples positive (Table 4). Additionally, we probed the peptides with DENV-seropositive (serotypes 1–4) and WNV-seropositive (four pools, four sera in each) sera. None of the three positive peptides reacted with DENV or WNV seropositive sera, which reacted with some of the DENV and WNV peptides, respectively.
            Table 2

            Virus strains used for heterologous peptide synthesis

            Virus

            Strain

            GeneBank accession number

            TBEV

            European

            GU183380

            DENV1

            Singapore S275/90

            M87512

            DENV2

            New Guinea C

            AF038403

            DENV3

            strain H87

            M93130

            DENV4

            -

            AY94753

            LGTV

            -

            NC_003690

            OHFV

            -

            NC_005062

            LIV

            -

            NC_001809

            WNV

            Rabensburg isolate 97-103

            AY765264

            WNV

            isolate WN NY 2000-crow3356

            AF404756

            JEV

            -

            NC_001437

            USUV

            -

            NC_006551

            MVEV

            -

            NC_000943

            YFV

            17D vaccine

            NC_002031

            Table 3

            Paired TBEV-seropositive serum samples

            Sample

            Sample ID

            IgG

            IgM

            NT

            E-74/38

            E-85/59

            NS2B- 244/124

            NS5- 521/197

            NS5- 521/198

            NS5- 521/206

            Acute

            GG15-44

            +

            +

            <5

            -

            +

            +

            -

            -

            +

            Convalescent

            GG15-339

            +

            -

            40

            +

            +

            +

            +

            +

            +

            Acute

            GG5-36

            +

            +

            <5

            +

            +

            -

            -

            +

            -

            Convalescent

            GG5-198

            +

            -

            40

            -

            +

            -

            +

            +

            -

            Acute

            GG12-62

            +

            +

            5

            +

            +

            +

            +

            +

            +

            Convalescent

            GG12-286

            +

            -

            160

            +

            +

            +

            -

            +

            +

            Acute

            GG38-126

            +

            +

            <5

            +

            +

            +

            +

            +

            +

            Convalescent

            GG38-128

            +

            +

            5

            -

            +

            +

            -

            -

            -

            Acute

            GG33-102

            +

            +

            <5

            -

            -

            -

            -

            -

            -

            Convalescent

            GG33-344

            +

            -

            20

            -

            -

            +

            -

            -

            -

            Acute

            GG57-194

            +

            +

            <5

            -

            +

            -

            -

            +

            +

            Convalescent

            GG57-590

            +

            -

            40

            -

            +

            +

            +

            +

            +

            NT: neutralization titer. TBEV peptides in bold.

            Table 4

            Specificity of the selected peptide epitopes

            Protein

            Index

            Virus

            Peptide sequence

            TBEV

            Neg. controls

            Vaccinated

            WNV pools

            DENV (1, 2, 3 or 4)

            Overall sensitivity

            E

            56/7

            TBEV

            E N P A K T R E Y C L H A K L S D T

            3/6

            2/20

            3/8

            2/4

            2/4

            7/11

            E

            74/38

            TBEV

            A S F T V S S E K T I L T M G E Y G

            4/6

            2/20

            1/8

            0/4

            0/4

            8/11

            E

            85/59

            TBEV

            L A L P W K H E G A Q N W N N A E R

            5/6

            1/20

            0/8

            0/4

            0/4

            10/11

            NS1

            154/88

            TBEV

            E C P L E R R K T G V F T V A E F G

            3/6

            13/20

            2/8

            1/4

            0/4

            7/11

            NS2B

            244/124

            DENV2

            G L L V I S G L F P V S I P I T A A

            5/6

            2/20

            0/8

            2/4

            1/4

            9/11

            NS3

            340/142

            TBEV

            P W L A W H V A A N V S S V T D R S

            6/6

            9/20

            2/8

            2/4

            1/4

            10/11

            NS4B

            382/169

            TBEV

            S E W T N V D I Q P A R S W G T Y V

            1/6

            9/20

            0/8

            2/4

            0/4

            5/11

            NS5

            521/197

            TBEV

            L N T L T N I K V Q L I R M M E G E

            5/6

            2/20

            3/8

            0/4

            0/4

            9/11

            NS5

            521/198

            TBEV

            N T L T N I K V Q L I R M M E G E G

            5/6

            2/20

            1/8

            0/4

            0/4

            9/11

            NS5

            521/206

            DENV3

            G L N T F T N M E A Q L I R Q M E G

            4/6

            2/20

            7/8

            0/4

            0/4

            8/11

            NS5

            531/223

            TBEV

            P L D D R F G K A L Y F L N D M A K

            4/6

            6/20

            1/8

            0/4

            0/4

            8/11

            NS5

            532/250

            TBEV

            G K A L Y F L N D M A K T R K D I G

            2/6

            10/20

            1/8

            0/4

            0/4

            6/11

            NS5

            552/277

            TBEV

            W S I H A S G A W M T T E D M L D V

            3/6

            8/20

            1/8

            0/4

            0/4

            8/11

            Of these peptides, the peptide E-74/38 (aa 443-460/aa 162–179 of E) lies in the domain I and the peptide E-85/59 (aa 503-520/aa 222–239 of E) in the domain II of the E protein (Figure 2). Amino acid residues in peptide E-85/59 fell into a region that has been identified in low pH-induced fusion with endosomal membrane (residues 221–240) [13, 14]. Based on peptide sequence alignments, the minimal amino acid sequence for the peptide E-74/38 is 14 amino acids and it differed from the other tick-borne flaviviruses by a minimum of one C-terminal residue (Figure 3A). However, as shown in Figure 2C, peptide E-74/38 represents a region with two antiparallel beta-sheets, and thus most likely forms a conformational epitope. For the peptide E-85/59, the minimal sequence recognized is 16 amino acids and it shows very little or no homology to other flavivirus heterologous peptides (Figure 3B). Also, the reactivity towards the peptide E-85/59 represents most likely a response towards a conformational epitope formed by a protruding loop of domain II in TBEV E protein (Figure 2D). Peptide E-56/7 was found to cross-react with DENV and WNV sera pools. This peptide is located in domain II of the E protein (Figure 2A) and represents a long stretch of two beta sheets. This peptide would be only partially accessible in the virion, and most likely the C- and N-terminal portions of this peptide (separately) are involved in formation of a conformational epitope with other regions in domain II (Figure 2A).
            http://static-content.springer.com/image/art%3A10.1186%2F1743-422X-11-115/MediaObjects/12985_2014_2446_Fig2_HTML.jpg
            Figure 2

            Location of the identified peptide epitopes in E protein structure. Left-hand panels show the secondary structure (dimer) and right-hand panels show the solvent accessible surface (monomer) of E protein. A) TBEV E protein dimer as viewed from above (the virion) colored (domain I in red, domain II in yellow, and domain III in blue) according to Rey F et al. (Rey et al. [13]). B) Peptide E-56/7 (residues 51–58, in domain 2), highlighted in red. C) Peptide E-74/38 (residues 163–180, in domain 1), highlighted in red. D) Peptide E-85/59 (residues 223–240, in domain 2), highlighted in red. E) Peptides E-56/7, E-74/38, and E-85/59, highlighted in red.

            http://static-content.springer.com/image/art%3A10.1186%2F1743-422X-11-115/MediaObjects/12985_2014_2446_Fig3_HTML.jpg
            Figure 3

            Clustal 2.1 multiple sequence alignment of the synthesized heterologous peptides with A) TBEV E-74 B) TBEV E-85 C) TBEV NS5-521. The line separates peptides reactive with TBEV-seropositive sera (above) from the non-reactive ones. Identical amino acids in grey. Conserved amino acids marked with asterisks.

            The third identified linear epitope NS5-521/198 was in the C-terminal RNA-polymerase region of the NS5 protein (aa 3123-3140/aa 612–629) [6]. The minimal amino acid sequence for NS5-521/198 (Figure 3C) differs by a minimum of two amino acids from other tick-borne flaviviruses. The parent peptide 521 is identical to the corresponding peptide from Omsk hemorrhagic fever virus (OHFV, Figure 3C). However, the parent peptide yielded only borderline positive values in quantitation whereas more clearly positive values with less cross-reactivity were obtained with peptide NS5-521/198 containing two additional amino acids. Since a 3D structure is available for the NS5 of several flaviviruses, excluding TBEV, we used homology modeling to generate a model for TBEV NS5 structure. The peptide NS5-521/198 (Figure 4C) is located in the palm domain of TBEV NS5 (Figure 4B, residues 499–541 and 610–717). In addition, two of the other peptide epitopes (NS5-531/223 and NS5-532/250, Figure 4D and E, respectively, excluded due to cross-reactivity) in NS5 lie in the palm domain. The third dominant, but rather cross-reactive, epitope in NS5 (peptide NS5-552/277) is located in the thumb domain in the TBEV NS5 structure model (Figure 4F).
            http://static-content.springer.com/image/art%3A10.1186%2F1743-422X-11-115/MediaObjects/12985_2014_2446_Fig4_HTML.jpg
            Figure 4

            Three-dimensional model of TBEV NS5 structure with the identified peptide epitopes. A) Ribbon diagram of TBEV NS5 model. B) Palm domain of TBEV NS5 model (according to analogy to WNV NS5 (Malet et al., [28]), highlighted in yellow. C) Peptide NS5-521/198 (residues 612–629), highlighted in red. D) Peptide NS5-531/223 (residues 670–687), highlighted in red. E) Peptide NS5-532/250 (residues 676–683), highlighted in red. F) Peptide NS5-552/277 (residues 796–813), highlighted in red. G) Peptides NS5-521/198, NS5-531/223, and NS5-532/250, highlighted in red. H) Peptides NS5-521/198, NS5-531/223, NS5-532/250, and NS5-552/277, highlighted in red.

            Linear epitopes in natural versus vaccine-induced TBEV immunity

            Finally, to compare the B-cell epitope responses induced by vaccination and infection, we probed the new membrane with eight serum samples of persons immunized and showing neutralizing antibody responses against TBEV. None of the eight sera recognized the peptide E-85/59, suggesting that fixation used in virus inactivation might alter the conformation of this potentially conformational epitope (Figure 2D).

            One out of eight sera recognized the peptide E-74/38 that also likely represents a conformational epitope (Figure 2C, Table 4). The results summarizing the new membrane using individual serum samples are given in Table 4. Curiously, quite a strong cross-reactivity with a peptide from DENV3 NS5 (corresponding to the peptide NS5-521/206) was seen with the serum of several TBEV-immunized individuals (Table 4). Only 1/8 TBEV-immunized serum samples recognized the NS5-521/198 peptide (Table 4). Many of the sera from TBEV-immunized individuals reacted with peptide epitopes that were not recognized by sera of TBEV-infected and TBEV-seronegative individuals (Table 5). These peptides, mostly located in the E protein, could be rendered more antigenic due to fixation required for virus inactivation.
            Table 5

            Peptides specific for TBEV-immunized individuals

            Protein

            Index

            Peptide sequence

            prM

            24

            Q V R V E N G T C V I L A T D M G S

            prM

            29

            I D Q G E E P V D V D C F C R N V D

            E

            61

            T L A E E H Q G G T V C K R D Q S D

            E

            65

            C G L F G K G S I V A C V K A A C E

            E

            72

            T G D Y V A A N E T H S G R K T A S

            E

            88

            E F G A P H A V K M D V Y N L G D Q

            E

            95

            S G H V T C E V G L E K L K M K G L

            E

            96

            E V G L E K L K M K G L T Y T M C D

            E

            101

            S G H D T V V M E V T F S G T K P C

            E

            121

            L G G A F N S I F G G V G F L P K L

            E

            122

            S I F G G V G F L P K L L L G V A L

            Discussion

            Currently, TBE diagnostics is based on assays measuring IgM and IgG antibody responses to purified viral particles or consisting of structural proteins, or in some cases recombinant virus-like particles [15, 16]. TBEV E-protein is highly cross-reactive among other members of the genus Flavivirus and thus the identification of TBEV-specific antigenic regions would be beneficial. The cross-reactivity between flaviviruses is mainly due to conformational epitopes, and therefore linear epitopes presented as peptides could represent a useful alternative for traditionally used purified virus or recombinant protein diagnostic antigens. Ideally, such antigens could enable differential diagnostics between flaviviruses, and perhaps also between natural TBEV infection and vaccine responses. On the other hand, the potential of the nonstructural proteins as antigens is currently not fully explored. Our study provides one holistic approach for screening antigenic areas with diagnostic potential. For mosquito-borne flaviviruses, Wong et al. have developed an NS5-based serological test for differentiating natural WNV-infection from other flavivirus infections (specifically Saint Louis encephalitis and dengue virus) [17].

            In this study, we describe the mapping of linear B-cell IgG epitopes in the TBEV proteome. Initial mapping using TBEV-seronegative and acute TBEV-seropositive serum pools revealed several regions containing linear epitopes throughout the TBEV proteome. Further analysis of the epitope regions using individual serum samples revealed that most of the epitopes were not recognized by all of the positive samples. After data analysis, we selected 11 peptides in total from E, NS1, NS2B, NS3, NS4B and NS5 proteins for more thorough characterization. In addition, we addressed the cross-reactivity of TBEV seropositive sera against the corresponding regions from other flaviviruses. Eventually, we identified three TBEV-specific epitope regions that reacted with the majority of TBEV seropositive sera. Two of the identified peptides are in the E protein and one in the NS5 protein region. Of these, peptide E-85/59 showed the highest specificity and potential in serological differentiation between natural and vaccine-derived immunity. Holzmann et al. used a similar type of approach to study linear epitopes in TBEV E protein utilizing mouse monoclonal antibodies. Their results demonstrated that only few of the MAbs reacted with synthetic peptides from TBEV E protein. Curiously, these MAbs bound only TBEV E protein only if directly coated on microtitre plate or otherwise denatured [18]. However, in our study we were able to demonstrate several linear epitopes throughout TBEV E protein. Peptide E-85/59, the region identified by Holzmann et al. as an epitope for TBEV MAb, was recognized only by sera of infected individuals and not by sera of vaccinated individuals.The space-filling model of the E protein (Figure 2) demonstrates that the identified peptides lie on the surface of the folded protein. Furthermore, both E-74/38 and E-85/59 that are located in domains I and II, respectively, actually form or are parts of a conformational epitope (Figure 2C and D). Neither of these peptides was reactive with sera of TBEV-immunized individuals, thus suggesting that the conformational epitopes at these regions are affected by the fixation used for virus inactivation. Furthermore, we observed that the sera of TBEV-immunized individuals recognized several epitopes in the E protein that were less reactive with sera of naturally infected TBEV-seropositive individuals. This probably highlights the fact that the natural B-cell response towards TBEV, and perhaps towards flaviviruses in general, is based on conformational epitopes. Although vaccination using formalin-fixed inactivated virions is effective, stronger responses would obviously be obtained with replication in cells or with native proteins.

            We generated a homology model for TBEV NS5 to visualize the epitopes found in this region. The peptides NS5-521/198, NS5-531/223 and NS5-532/250 identified in this study, are located in the palm domain in the TBEV NS5 structure model. Of these peptides, NS5-521/198 is identical to the respective region in Omsk hemorrhagic virus NS5. The parent peptide reacted (positive with 6/6 of TBE patient and 3/20 of seronegative samples) rather similarly with the OMSKV peptide (positive with 4/6 of TBE patient and 3/20 of seronegative samples). Thus it seems evident that OMSKV-seropositive serum would also recognize this peptide epitope. However, since a couple of epitopes are located in the palm domain of TBEV NS5, one could envision using this region as recombinant antigen for flavivirus diagnostics.

            Throughout our study we used densitometry to quantify the signal intensities of the individual peptides on the SPOT array. However, since the detection of SPOT binding is based on an enzymatic reaction, many factors contribute to the signal intensity (incubation and exposure times, membrane regeneration, antibody dilutions, ECL reagents, etc.). Quantification can therefore be done only inside the array and not between individual serum samples. Due to this, we evaluated each membrane individually, and considered peptides positive if the intensity was above a certain assay-specific threshold value. However, this method brings out a challenge in selecting the true-positive peptides, and vice versa, it is likely to miss some potential spots under the arbitrary threshold. As exemplified by a slight discrepancy in the results obtained with DENV2 (3/6 were positive) and DENV3 (4/6 were positive) peptides having identical sequences. This discrepancy is directly explained by the selected threshold values and the factors described above. Additionally, the regeneration steps required for re-use of the SPOT peptide array membranes are not ideal for high throughput screening. Thus we will, in the near future, synthesize some of the promising peptides found in this study in soluble form, and use them as antigens in an enzyme-linked immunosorbent assay (ELISA) format. ELISA will allow us to further test these peptides with larger serum panels and at different dilutions.

            Conclusions

            In conclusion, we have for the first time characterized the linear human B-cell epitopes of TBEV using TBE-patient and cross-reacting flavivirus sera. The TBE patients’ sera detect peptide targets particularly on the surface of E and NS5 proteins, and two of these peptides seem promising in distinguishing between TBEV and other flavivirus infections or TBEV vaccine derived immunity.

            Methods

            Computer analysis

            The putative hydrophobic and hydrophilic areas of the coding region of TBEV European subtype strain Kumlinge A52 genome (GenBank accession number GU183380) [19, 20] were predicted by the Kyte and Doolittle method using MacVector software.

            Peptide synthesis

            The whole coding region of TBEV genome strain Kumlinge A52 was synthesized onto an amino-PEG membrane in 567 18-amino acid peptides with six amino acid transition [21]. Based on the initial screening with 567 peptides covering the proteome of TBEV, we selected 11 peptides (Table 1) for further evaluation. Six amino acids were added to both N- and C-terminus of these peptides, which were then synthesized as 18-amino acid peptides with one amino acid transition. Heterologous peptides corresponding to the “parent” peptide (Table 2) were synthesized from other tick- and mosquito-borne flaviviruses. Peptide synthesis was conducted with a MultiPep platform (Intavis Ag) utilizing Fmoc chemistry as described earlier [22].

            SPOT method

            The membrane containing the complete proteome of TBEV was initially probed with a pool of sera from TBEV seronegative patients (N = 5), next with a pool of sera from TBEV-immunized individuals (N = 8), then with a pool of sera from TBE patients (N = 5), and finally with individual serum samples collected from acute-phase TBE patients (N = 5). The membrane with peptides selected based on initial screening (11 “parent” peptides, Table 1) was probed individually with six paired serum samples from acute-phase TBE patients and with sera from 8 TBEV-immunized individuals. The probing and detection of SPOT membranes was done as previously described [23]. Briefly, the sera were used at 1:500 dilution (in pools the total serum dilution was 1:500). The binding of antibodies was detected by HRP-labeled anti-human IgG (DakoCytomation) at 1:1000 dilution and the results were visualized utilizing enhanced chemiluminescence as recorded on X-ray film (Fuji RX medical).

            Serum samples

            Five acute-phase TBEV-seropositive and five TBEV-seronegative patient sera were selected from serum samples sent to and tested at the Helsinki University Central Hospital Laboratory (HUSLAB), Department of Virology and Immunology. TBEV-seropositive sera were IgM and IgG positive in routinely used serological tests.

            The panel of 6 paired serum samples of acute TBE patients and eight serum samples of TBEV-immunized people were collected in Sweden. These sera were characterized by neutralization inhibition at The Public Health Agency of Sweden, Solna, Sweden. The samples of immunized individuals were taken before and after the third vaccine dose of the TBEV vaccination programme. Both sample sets were found TBEV IgM and IgG positive in routinely used serological tests at HUSLAB, Department of Virology and Immunology.

            Four pools of WNV patient sera were obtained through ENIVD network (European Network on Improted Viral Diseases, http://​www.​enivd.​de). A total of four DENV IgM and IgG positive patient serum samples (each representing primary infections with a different serotype, DENV-1-4), as determined by RT-PCR [24] were selected from patient samples sent to and tested at HUSLAB, Department of Virology and Immunology.

            Densitometric analysis of peptide intesinty

            The results of SPOT analysis recorded on X-ray film were scanned using flatbed scanner (CanoScan LIDE 70) as TIFF files. The SPOT intensities were quantitated using Chemidoc XRS (Bio-Rad). Specific threshold values were assigned for each array individually.

            Protein structures and homology modelling

            To visualize the peptide epitopes discovered, we generated a three-dimensional model for TBEV A52 Kumlinge NS5 protein structure using Swiss-Model in Automatic Modelling Mode [25]. Swiss-Model chose WNV NS5 protein (pdb code 2HFZ) [2629] with a sequence identity of 62.1% to TBEV NS5 as the template for model building. The generated model had a QMEAN6 score of 0.652 with a Z-Score of −1.227 [30]. Based on the QMEAN6 score, we estimated the model to be accurate enough for visualization of the peptide epitopes.

            The TBEV E protein structure (1SVB) was obtained from the protein data bank. The domains of E protein were colored as previously described [13] using YASARA [31]. The epitope peptides were highlighted in both TBEV NS5 model and in TBEV E protein structure using YASARA.

            Declarations

            Acknowledgements

            This study was supported by Jenny and Antti Wihuri Foundation.

            Authors’ Affiliations

            (1)
            Department of Virology, Haartman Institute, Faculty of Medicine, University of Helsinki
            (2)
            Department of Virology and Immunology, Helsinki University Central Hospital Laboratory (HUSLAB)
            (3)
            Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki
            (4)
            The Public Health Agency of Sweden

            References

            1. Lindquist L, Vapalahti O: Tick-borne encephalitis. Lancet 2008,371(9627):1861–1871.PubMedView Article
            2. Holzmann H, Aberle SW, Stiasny K, Werner P, Mischak A, Zainer B, Netzer M, Koppi S, Bechter E, Heinz FX: Tick-borne encephalitis from eating goat cheese in a mountain region of Austria. Emerg Infect Dis 2009,15(10):1671–1673.PubMed CentralPubMedView Article
            3. Hudopisk N, Korva M, Janet E, Simetinger M, Grgic-Vitek M, Gubensek J, Natek V, Kraigher A, Strle F, Avsic-Zupanc T: Tick-borne encephalitis associated with consumption of raw goat milk, Slovenia, 2012. Emerg Infect Dis 2013,19(5):806–808.PubMed CentralPubMedView Article
            4. Ecker M, Allison SL, Meixner T, Heinz FX: Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. J Gen Virol 1999,80(Pt 1):179–185.PubMed
            5. Chambers TJ, Nestorowicz A, Amberg SM, Rice CM: Mutagenesis of the yellow fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication. J Virol 1993,67(11):6797–6807.PubMed CentralPubMed
            6. Koonin EV: Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus. J Gen Virol 1993,74(Pt 4):733–740.PubMedView Article
            7. Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH: Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 1985,229(4715):726–733.PubMedView Article
            8. Mackenzie JM, Khromykh AA, Jones MK, Westaway EG: Subcellular localization and some biochemical properties of the flavivirus Kunjin nonstructural proteins NS2A and NS4A. Virology 1998,245(2):203–215.PubMedView Article
            9. Mason PW, Zugel MU, Semproni AR, Fournier MJ, Mason TL: The antigenic structure of dengue type 1 virus envelope and NS1 proteins expressed in Escherichia coli. J Gen Virol 1990,71(Pt 9):2107–2114.PubMedView Article
            10. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G: Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010,328(5979):745–748.PubMedView Article
            11. Cardosa MJ, Wang SM, Sum MS, Tio PH: Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses. BMC Microbiol 2002, 2:9.PubMed CentralPubMedView Article
            12. AnandaRao R, Swaminathan S, Khanna N: The identification of immunodominant linear epitopes of dengue type 2 virus capsid and NS4a proteins using pin-bound peptides. Virus Res 2005,112(1–2):60–68.PubMedView Article
            13. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC: The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995,375(6529):291–298.PubMedView Article
            14. Roehrig JT, Bolin RA, Kelly RG: Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus. Jamaica Virology 1998,246(2):317–328.View Article
            15. Jaaskelainen A, Han X, Niedrig M, Vaheri A, Vapalahti O: Diagnosis of tick-borne encephalitis by a mu-capture immunoglobulin M-enzyme immunoassay based on secreted recombinant antigen produced in insect cells. J Clin Microbiol 2003,41(9):4336–4342.PubMed CentralPubMedView Article
            16. Levanov L, Kuivanen S, Matveev A, Swaminathan S, Hakala AJ, Vapalahti O: Diagnostic potential and antigenic properties of recombinant tick-borne encephalitis virus subviral particles expressed in mammalian cells from Semliki Forest virus replicon. J Clin Microbiol 2014,52(3):814–22. Epub 2013 Dec 26.PubMedView Article
            17. Wong SJ, Boyle RH, Demarest VL, Woodmansee AN, Kramer LD, Li H, Drebot M, Koski RA, Fikrig E, Martin DA, Shi PY: Immunoassay targeting nonstructural protein 5 to differentiate West Nile virus infection from dengue and St. Louis encephalitis virus infections and from flavivirus vaccination. J Clin Microbiol 2003,41(9):4217–4223.PubMed CentralPubMedView Article
            18. Holzmann H, Utter G, Norrby E, Mandl CW, Kunz C, Heinz FX: Assessment of the antigenic structure of tick-borne encephalitis virus by the use of synthetic peptides. J Gen Virol 1993,74(Pt 9):2031–2035.PubMedView Article
            19. BRUMMER-KORVENKONTIO M, SALMINEN A, OKER-BLOM N: Hemagglutination-inhibiting antibodies to tick-borne encephalitis virus in mammals and birds. Acta Pathol Microbiol Scand Suppl 1962, 154:337–338.PubMed
            20. Uzcategui NY, Sironen T, Golovljova I, Jaaskelainen AE, Valimaa H, Lundkvist A, Plyusnin A, Vaheri A, Vapalahti O: Rate of evolution and molecular epidemiology of tick-borne encephalitis virus in Europe, including two isolations from the same focus 44 years apart. J Gen Virol 2012,93(Pt 4):786–796.PubMedView Article
            21. Frank R: The SPOT-synthesis technique: synthetic peptide arrays on membrane supports--principles and applications. J Immunol Methods 2002,267(1):13–26.PubMedView Article
            22. Hepojoki J, Strandin T, Wang H, Vapalahti O, Vaheri A, Lankinen H: Cytoplasmic tails of hantavirus glycoproteins interact with the nucleocapsid protein. J Gen Virol 2010,91(Pt 9):2341–2350.PubMedView Article
            23. Hepojoki J, Strandin T, Vaheri A, Lankinen H: Interactions and oligomerization of hantavirus glycoproteins. J Virol 2010,84(1):227–242.PubMed CentralPubMedView Article
            24. Huhtamo E, Hasu E, Uzcategui NY, Erra E, Nikkari S, Kantele A, Vapalahti O, Piiparinen H: Early diagnosis of dengue in travelers: comparison of a novel real-time RT-PCR, NS1 antigen detection and serology. J Clin Virol 2010,47(1):49–53.PubMedView Article
            25. Swiss-Model. Available at http://​swissmodel.​expasy.​org/​. Accessed March 4, 2014.
            26. Arnold K, Bordoli L, Kopp J, Schwede T: The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006,22(2):195–201.PubMedView Article
            27. Guex N, Peitsch MC: SWISS-MODEL and the swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997,18(15):2714–2723.PubMedView Article
            28. Malet H, Egloff MP, Selisko B, Butcher RE, Wright PJ, Roberts M, Gruez A, Sulzenbacher G, Vonrhein C, Bricogne G, Mackenzie JM, Khromykh AA, Davidson AD, Canard B: Crystal structure of the RNA polymerase domain of the West Nile virus non-structural protein 5. J Biol Chem 2007,282(14):10678–10689.PubMedView Article
            29. Schwede T, Kopp J, Guex N, Peitsch MC: SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003,31(13):3381–3385.PubMed CentralPubMedView Article
            30. Benkert P, Biasini M, Schwede T: Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics 2011,27(3):343–350.PubMed CentralPubMedView Article
            31. YASARA. Available at http://​www.​yasara.​org/​.

            Copyright

            © Kuivanen et al.; licensee BioMed Central Ltd. 2014

            This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

            Advertisement